Kidney Cancer

Aspirin Safe for Partial Nephrectomy Patients

Aspirin Safe for Partial Nephrectomy Patients

Findings among patients on chronic antiplatelet therapy for cardioprotection.

Positive Margins After Partial Nephrectomy Raises Death Risk

Positive Margins After Partial Nephrectomy Raises Death Risk

By

Positive surgical margins are associated with a significant 34% increased risk of all-cause mortality.

Higher NLR Predicts More Aggressive Kidney Cancer

Higher NLR Predicts More Aggressive Kidney Cancer

By

Elevated neutrophil-to-lymphocyte ratio is associated with larger tumors and greater nuclear grade.

Partial Nephrectomy Protects Against ESRD

Partial Nephrectomy Protects Against ESRD

By

Nephron-sparing surgery decreased the risk of end-stage renal disease by 60% in select patients.

Proteinuria Signals Renal Function Decline in Kidney Cancer

Proteinuria Signals Renal Function Decline in Kidney Cancer

Proteinuria is a predictor for renal functional decline in patients with kidney cancer.

Core-Needle Biopsy Aids RCC Diagnosis

Core-Needle Biopsy Aids RCC Diagnosis

Image-guided testing of tissue from the renal mass may lead to improved treatments, researchers say.

Papillary RCC More Common in African Americans

Papillary RCC More Common in African Americans

By

Racial difference found among patients undergoing robotic partial nephrectomy for renal tumors.

Papillary RCC More Common in African Americans

Papillary RCC More Common in African Americans

By

Racial difference found among patients undergoing robotic partial nephrectomy for renal tumors.

Renal Mass Biopsy for a Small Renal Mass Can Be Accurate

Renal Mass Biopsy for a Small Renal Mass Can Be Accurate

Between renal mass biopsy, surgical pathology, rate of accuracy in identifying malignancies 97.1%.

Renal Mass Biopsy for a Small Renal Mass Can Be Accurate

Renal Mass Biopsy for a Small Renal Mass Can Be Accurate

Between renal mass biopsy, surgical pathology, rate of accuracy in identifying malignancies 97.1%.

Prostate Cancer Risk Lower in Type 2 Diabetics

Prostate Cancer Risk Lower in Type 2 Diabetics

By

In contrast, type 2 diabetes is associated with increased risks of bladder, kidney, liver, and other malignancies.

Robotic Nephrectomy of Kidney Tumors With Thrombi Feasible

Robotic Nephrectomy of Kidney Tumors With Thrombi Feasible

A retrospective study has shown that the procedure is feasible and was performed safely in selected patients with renal tumors.

Adjuvant Therapies: Time to Fold or Double Down?

Adjuvant Therapies: Time to Fold or Double Down?

Benjamin T Ristau, MD, and Robert G. Uzzo, MD, FACS, examine why adjuvant therapies have been so ineffective.

Researchers Calculate Inherited Cancer Risk from Genes

Researchers Calculate Inherited Cancer Risk from Genes

Estimated 33% of overall risk is genetic; certain types of cancer have additional risk.

NSAIDs May Raise Risk of Fatal Kidney Cancer

NSAIDs May Raise Risk of Fatal Kidney Cancer

By

Regular use of non-steroidal anti-inflammatory drugs for 10 years or more increased the risk of dying from renal cell carcinoma nearly 4-fold.

NSAIDs May Raise Risk of Fatal Kidney Cancer

NSAIDs May Raise Risk of Fatal Kidney Cancer

By

Regular use of non-steroidal anti-inflammatory drugs for 10 years or more increased the risk of dying from renal cell carcinoma nearly 4-fold.

Nephrectomy as Initial mRCC Treatment Offers Survival Advantage

Nephrectomy as Initial mRCC Treatment Offers Survival Advantage

By

Patients who underwent upfront cytoreductive nephrectomy lived 6.4 months longer than those treated with upfront targeted therapy, a study found.

Nephrectomy as Initial mRCC Treatment Offers Survival Advantage

Nephrectomy as Initial mRCC Treatment Offers Survival Advantage

By

Patients who underwent upfront cytoreductive nephrectomy lived 6.4 months longer than those treated with upfront targeted therapy, a study found.

Metformin Lowers Death Risk in mRCC Patients on Sunitinib

Metformin Lowers Death Risk in mRCC Patients on Sunitinib

By

The protective effect was not observed with other anti-diabetic medications.

Metformin Lowers Death Risk in mRCC Patients on Sunitinib

Metformin Lowers Death Risk in mRCC Patients on Sunitinib

By

The protective effect was not observed with other anti-diabetic medications.

Cabozantinib Improves PFS in Patients With Advanced RCC

Cabozantinib Improves PFS in Patients With Advanced RCC

By

The drug nearly doubled the delay in tumor growth compared with everolimus.

RCC Surgery Outcomes Not Worse in Extremely Obese Patients

RCC Surgery Outcomes Not Worse in Extremely Obese Patients

By

Study reveals no significant differences in hospital readmission rates and overall, cancer-specific, and recurrence-free survival rates.

RCC Surgery Outcomes Not Worse in Extremely Obese Patients

RCC Surgery Outcomes Not Worse in Extremely Obese Patients

By

Study reveals no significant differences in hospital readmission rates and overall, cancer-specific, and recurrence-free survival rates.

FDA Approves New Drug for Advanced Kidney Cancer

FDA Approves New Drug for Advanced Kidney Cancer

By

Nivolumab is cleared for treating patients with metastatic RCC whose disease advanced despite prior treatment with anti-angiogenic therapy.

FDA Approves New Drug for Advanced Kidney Cancer

FDA Approves New Drug for Advanced Kidney Cancer

By

Nivolumab is cleared for treating patients with metastatic RCC whose disease advanced despite prior treatment with anti-angiogenic therapy.

Diabetes Predicts Worse Survival in RCC Patients Treated Surgically

Diabetes Predicts Worse Survival in RCC Patients Treated Surgically

For patients with diabetes, poor glycemic control linked to higher risk of post-operative progression.

Diabetes Predicts Worse Survival in RCC Patients Treated Surgically

Diabetes Predicts Worse Survival in RCC Patients Treated Surgically

For patients with diabetes, poor glycemic control linked to higher risk of post-operative progression.

Type 1, Type 2 Papillary Renal Cell Carcinomas Biologically Distinct

Type 1, Type 2 Papillary Renal Cell Carcinomas Biologically Distinct

Specific alterations seen in type 1 and type 2 carcinomas; type 2 consists of at least 3 subtypes.

Type 1, Type 2 Papillary Renal Cell Carcinomas Biologically Distinct

Type 1, Type 2 Papillary Renal Cell Carcinomas Biologically Distinct

Specific alterations seen in type 1 and type 2 carcinomas; type 2 consists of at least 3 subtypes.

ESRD and Treatments May Raise Cancer Risk

ESRD and Treatments May Raise Cancer Risk

Dialysis, organ transplant may increase odds for certain types of cancer.

Sign Up for Free e-newsletters